.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Cerilliant
Mallinckrodt
Chubb
Cantor Fitzgerald
Healthtrust
Boehringer Ingelheim
Dow
Express Scripts
QuintilesIMS

Generated: December 14, 2017

DrugPatentWatch Database Preview

Genentech Inc Company Profile

« Back to Dashboard

What is the competitive landscape for GENENTECH INC, and when can generic versions of GENENTECH INC drugs launch?

GENENTECH INC has three approved drugs.

There are twenty-two US patents protecting GENENTECH INC drugs.

There are two hundred and fifty-nine patent family members on GENENTECH INC drugs in forty-four countries and six supplementary protection certificates in six countries.

Summary for Genentech Inc

International Patents:259
US Patents:22
Tradenames:2
Ingredients:2
NDAs:3
Drug Master File Entries: 7
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Genentech IncESBRIETpirfenidoneCAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Genentech IncESBRIETpirfenidoneTABLET;ORAL208780-003Jan 11, 2017RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Genentech IncESBRIETpirfenidoneTABLET;ORAL208780-003Jan 11, 2017RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Genentech IncESBRIETpirfenidoneCAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Genentech IncESBRIETpirfenidoneCAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Genentech IncESBRIETpirfenidoneTABLET;ORAL208780-003Jan 11, 2017RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Genentech IncESBRIETpirfenidoneTABLET;ORAL208780-003Jan 11, 2017RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Genentech IncESBRIETpirfenidoneTABLET;ORAL208780-001Jan 11, 2017RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Genentech IncESBRIETpirfenidoneTABLET;ORAL208780-003Jan 11, 2017RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Genentech IncESBRIETpirfenidoneCAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Genentech Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,017,166,523► Subscribe
9,017,722Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone► Subscribe
7,867,516Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient► Subscribe
7,915,250Azetidines as MEK inhibitors for the treatment of proliferative diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Genentech Inc Drugs

Country Document Number Estimated Expiration
South Korea20120097418► Subscribe
Japan5837732► Subscribe
Austria526024► Subscribe
European Patent Office3143997► Subscribe
Serbia51782► Subscribe
Eurasian Patent Organization201691142► Subscribe
Serbia51976► Subscribe
Canada2620380► Subscribe
Japan5753094► Subscribe
JapanWO2002060446► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Genentech Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016016Lithuania► SubscribePRODUCT NAME: KOBIMETINIBAS; REGISTRATION NO/DATE: EU/1/15/1048 20151120
078Luxembourg► SubscribePRODUCT NAME: COBIMETINIB, EVENTUELLEMENT SOUS TOUTE FORME PROTEGEE PAR LE BREVET DE BASE, Y COMPRIS LES SELS ET SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER HEMIFUMARATE DE COBIMETINIB; FIRST REGISTRATION DATE: 20151124
2016 00021Denmark► SubscribePRODUCT NAME: COBIMETINIB, EVENTUELT I EN HVILKEN SOM HELST FORM BESKYTTET AF GRUNDPATENTET, DER INDBEFATTER FARMACEUTISK ACCEPTABLE SALTE OG SOLVATER, SAERLIGT COBIMETINIB HEMIFUMARAT; REG. NO/DATE: EU/1/15/1048 20151124
C0021France► SubscribePRODUCT NAME: COBIMETINIB,OPTIONNELLEMENT SOUS TOUTE FORME PROTEGEE PAR LE BREVET DE BASE,NOTAMMENT SES SELS ET SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES,EN PARTICULIER L'HEMIFUMARATE DE COBIMETINIB; REGISTRATION NO/DATE: EU/1/15/1048 20151124
0160012 00193Estonia► SubscribePRODUCT NAME: KOBIMETINIIB;REG NO/DATE: EU/1/15/1048 24.11.2015
0809Netherlands► SubscribePRODUCT NAME: COBIMETINIBI, DESGEWENST FARMACEUTISCH AANVAARDBARE ZOUTEN EN SOLVATEN DAARVAN, IN HET BIJZONDER COBIMETINIB HEMIFUMARAAT; REGISTRATION NO/DATE: EU/1/15/1048 20151124
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Novartis
Argus Health
Julphar
Deloitte
Farmers Insurance
Teva
Federal Trade Commission
US Army
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot